Phase I Evaluation of IRL757 Safety and Tolerability in Apathy Associated with Neurodegenerative Disorders in Healthy Volunteers

The primary objective of this study is to evaluate the **safety** and **tolerability** of single and multiple ascending oral doses of IRL757 in healthy volunteers. This is clinically relevant as it aims to establish the initial safety profile of IRL757, which is crucial for determining its potential therapeutic use in treating **apathy** associated with **neurodegenerative disorders**. Understanding the safety and tolerability in a healthy population is a foundational step before considering further clinical trials in patients with the target condition.

The clinical trial focuses on **apathy in neurodegenerative disorders** and includes both male and female participants. The study population encompasses adults, as indicated by the age range category code "3," which typically refers to individuals aged 18 and above. Participants are not considered part of a vulnerable population. The sponsor has not provided information regarding the total number of participants involved in the trial. The selection criteria for the trial population, including any specific lifestyle considerations such as diet, physical activity, or habits, have not been disclosed. Additionally, key inclusion or exclusion criteria have not been specified by the sponsor.

The clinical trial is a **randomized**, **double-blind**, **placebo-controlled** study designed to evaluate the safety and tolerability of single and multiple ascending oral doses of IRL757 in healthy volunteers. This **phase I** trial is conducted at a single center and is the first-in-human (FIH) study. The trial aims to assess the effects of the investigational product on **apathy in neurodegenerative disorders**. The estimated recruitment start date is April 1, 2024, with an anticipated end date of December 31, 2024, indicating an overall trial duration of approximately nine months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. Following successful screening, participants will be randomized to receive either the investigational product or a placebo. The study will include multiple follow-up visits to monitor safety, tolerability, and any adverse events. These visits will involve clinical assessments, laboratory tests, and other evaluations as necessary. The end-of-study visit will conclude the participant's involvement, during which final assessments will be conducted to ensure participant safety and collect final data.

The expected length of participant involvement will vary depending on the dosing schedule and the number of follow-up visits required. Participants may be withdrawn from the study early if they experience significant adverse events, fail to comply with study procedures, or withdraw consent. The study is designed to ensure the safety and well-being of participants while providing valuable data on the investigational product's effects in a controlled setting.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an initial investigation into the safety and potential efficacy of the intervention. The estimated recruitment start date is April 1, 2024, with an anticipated completion by December 31, 2024. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, typical Phase 1 trials often focus on safety and pharmacokinetics, with preliminary efficacy assessments. The trial will likely involve regular monitoring and data collection at predetermined intervals to evaluate the intervention's impact. The analysis will be conducted using scientifically validated methods appropriate for early-phase trials, ensuring the reliability and validity of the findings.